Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18286641 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HPGDHTR7AOC3HTT | |
| SCHEMBL21503575 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HPGDHTR7AOC3HTT | |
| SCHEMBL13792137 | 0.94 | ALDH1A1 (0.41) | ALDH1A1HPGDHTT | |
| SCHEMBL9746668 | 0.88 | RIPK1 (0.43) | — | |
| SCHEMBL15870930 | 0.87 | ALDH1A1 (0.47) | ALDH1A1HPGDHTR7AOC3HTT | |
| SCHEMBL9278852 | 0.87 | HTR7 (0.40) | ALDH1A1HPGDHTR7SLC6A2SLC6A3 | |
| SCHEMBL9232425 | 0.87 | HTR7 (0.40) | ALDH1A1HPGDHTR7SLC6A2SLC6A3 | |
| SCHEMBL22649183 | 0.85 | HTR7 (0.39) | ALDH1A1HPGDHTR7SLC6A2SLC6A3 | |
| SCHEMBL8217828 | 0.85 | HTR7 (0.39) | ALDH1A1HPGDHTR7SLC6A2SLC6A3 | |
| SCHEMBL21536775 | 0.84 | PSMD14 (0.41) | ALDH1A1HPGDHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102797043-A | Medicinal molecular fragment library and construction method thereof | CBB NETWORK CO LTD | 2012-11-28 | — | — | CN | claimed |
| CN-1640912-A | Polyaryl-ether-ketone viscosity regulator synthesized based on A2+B3 type monomer reaction and method therefor | UNIV JILIN (CN) | 2005-07-20 | — | — | CN | claimed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-11744826-B2 | Compounds and methods of treating retinal degeneration | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023164237-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-04-27 | — | — | US | disclosed |
| US-11578071-B2 | Preparation of pyrazolo[3,4-B]pyridines as antimalarials | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| US-11530197-B2 | Analogs for the treatment of disease | INSILICO MEDICINE IP LIMITED (HK) | 2022-12-20 | — | — | US | disclosed |
| CN-102097654-A | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery | MITSUBISHI CHEM CORP | 2011-06-15 | — | — | CN | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| CN-101432923-A | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery | MITSUBISHI CHEM CORP (JP) | 2009-05-13 | — | — | CN | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| CN-101277740-A | Antituberculous compositions comprising * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-10-01 | — | — | CN | disclosed |
| CN-100402581-C | Polyaryl-ether-ketone viscosity regulator synthesized based on A2+B3 type monomer reaction and method therefor | UNIV JILIN (CN) | 2008-07-16 | — | — | CN | disclosed |
| CN-100360584-C | Method of synthesizing fluorine containing superbranched light wave conductive material based on A2+B3 type monomer reaction | UNIV JILIN (CN) | 2008-01-09 | — | — | CN | disclosed |
| CN-1640912-A | Polyaryl-ether-ketone viscosity regulator synthesized based on A2+B3 type monomer reaction and method therefor | UNIV JILIN (CN) | 2005-07-20 | — | — | CN | disclosed |
| US-4152529-A | Dealkylation of halogenated alkyl substituted phenols | UOP INC. (US) | 1979-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | MERTK, DAPK1, AXL | ALDH1A1 1072/4885HPGD 3991/4885HTR7 4582/4885 |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | ALDH1A1 4332/4885HPGD 270/4885HTR7 3050/4885 |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | AURKA, AURKC, AURKB | ALDH1A1 2071/4885HPGD 3787/4885HTR7 3873/4885 |
| US-11578071-B2 | Preparation of pyrazolo[3,4-B]pyridines as antimalarials | PNPO, NOX3, G6PD | ALDH1A1 2771/4885HPGD 1896/4885HTR7 2469/4885 |
| US-11530197-B2 | Analogs for the treatment of disease | MAP4K4, MAP4K5, MAP4K2 | ALDH1A1 2948/4885HPGD 1580/4885HTR7 3201/4885 |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | MERTK, DAPK1, AXL | ALDH1A1 1072/4885HPGD 3991/4885HTR7 4582/4885 |
| US-11744826-B2 | Compounds and methods of treating retinal degeneration | ALDH1A2, PDE6D, PDE6C | ALDH1A1 212/4885HPGD 238/4885HTR7 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.